Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative

Simply Wall St.02-28

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614089991?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-28 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614089991","market":"us","top_or_hot":-1,"title":"Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative","media":"Simply Wall St.","content":"<div>\n<p>Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 09:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel","article_id":"2614089991","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/xenon-pharmaceuticals-xene-loss-widening-tests-bullish-pipel","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614089991","pubTimestamp":1772242702,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BLSX":"Tradr 2X Long BLSH Daily ETF","BK4139":"生物科技","XENE":"Xenon制药","BLSG":"2倍做多BLSH ETF-Leverage Shares"},"translate_title":"Xenon Pharmaceuticals XENE亏损扩大考验看涨管道叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":1.98,"BLSX":0.6,"BLSG":0.6},"content_text":"Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping margins firmly in loss making territory. See our full analysis for Xenon Pharmaceuticals. With the headline figures on the board, the next step is to see how these results line up against the most common narratives around Xenon Pharmaceuticals, and where the numbers start to challenge those views. See what the community is saying about Xenon Pharmaceuticals NasdaqGM:XENE Earnings & Revenue History as at Feb 2026 AdvertisementLosses widen faster than revenue ramps  Net income moved from a loss of US$105.9 million in the first half of 2024 to a loss of US$149.8 million in the first half of 2025, with trailing twelve month losses at US$345.9 million alongside a trailing EPS loss of US$4.36. Consensus narrative highlights azetukalner as a future earnings driver, and these figures put numbers around that optimism:\n     Analysts are assuming revenue could grow about 55% per year, yet the company is still reporting US$7.5 million of trailing revenue against US$345.9 million of trailing losses, so the income statement is still heavily skewed to costs. To support the view that earnings can eventually improve, the business would need to move from the current loss of roughly US$306.3 million cited in the consensus assumptions toward the US$45.7 million earnings figure they reference for 2028, which is a very large swing in profit dollars.    Premium P/B despite ongoing losses  The shares trade on a P/B of 5.9x versus about 2.7x for the broader US biotech group and 4.8x for peers, even though trailing twelve month net income is a loss of US$345.9 million and EPS is a loss of US$4.36. Critics point to the bearish angle that rich multiples leave little room for error while the company remains unprofitable:\n     Losses have grown at about 35.8% annually over the past five years, and the data suggests the business is expected to stay unprofitable for at least the next three years, which leans into that cautious view. At the same time, with revenue so far at US$7.5 million and no positive EPS yet, the current 5.9x P/B multiple is being supported more by expectations around the pipeline than by current profitability metrics.    On these numbers, some investors will want to stress test how much downside they see if the bearish case around profitability and rich multiples plays out before growth catches up. 🐻 Xenon Pharmaceuticals Bear Case Upside implied versus price and fair value  At a share price of US$43.23, the stock is described as trading well below a DCF fair value of about US$335.67, while the allowed analyst price target of US$56.27 implies around 30% upside versus today. Supporters lean on a bullish framing that growth and the pipeline can justify that gap, but the earnings profile sets a high bar:\n     The scenario that backs the US$56.27 target assumes revenue rising to US$284.9 million and earnings reaching US$45.7 million, which is a large change from the trailing revenue of US$7.5 million and loss of US$345.9 million. Because analysts also expect shares outstanding to grow about 1% per year for the next three years, any future EPS improvement has to offset both that share count effect and the current EPS loss of US$4.36 to line up with the bullish expectations.    If you want to see how different growth and margin paths could support that gap between US$43.23 and the bullish targets, it is worth stepping through the full bull case in detail. 🐂 Xenon Pharmaceuticals Bull Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xenon Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With both risks and rewards on the table, do these numbers leave you feeling confident or cautious, and how quickly do you want to firm up your stance? Take a closer look at the full picture so you can weigh the trade off for yourself, then review the 3 key rewards and 1 important warning sign to see what stands out most for your own thesis. See What Else Is Out There Xenon Pharmaceuticals is still carrying large losses of US$345.9 million against only US$7.5 million of trailing revenue, with profitability yet to emerge. If that mix of deep losses and rich expectations feels uncomfortable, you may want to balance your watchlist with 76 resilient stocks with low risk scores, which is built to highlight companies where risk scores look more restrained.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614089991","isCrawlerRequest":true}